B of A Securities Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $149

Benzinga Newsdesk www.benzinga.com Positive 83.7%

Neg 0% Neu 0% Pos 83.7%

B of A Securities analyst Tazeen Ahmad maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $139 to $149.